Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Susceptibility to paromomycin in clinical isolates and reference strains of Leishmania species responsible for tegumentary leishmaniasis in Brazil

Full text
Author(s):
Coser, Elizabeth M. [1] ; Ferreira, Bianca A. [1] ; Yamashiro-Kanashiro, Edite H. [2, 3] ; Lindoso, Jose Angelo L. [4, 5] ; Coelho, Adriano C. [1]
Total Authors: 5
Affiliation:
[1] Univ Estadual Campinas UNICAMP, Inst Biol, Dept Biol Anim, Campinas - Brazil
[2] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Lab Soroepidemiol & Imunobiol, Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Lab Imunol LIM 48, Sao Paulo - Brazil
[4] Inst Infectol Emilio Ribas, Sao Paulo - Brazil
[5] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Lab Protozool, Inst Med Trop Sao Paulo, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Acta Tropica; v. 215, MAR 2021.
Web of Science Citations: 1
Abstract

Treatment of tegumentary leishmaniasis in Brazil is limited to pentavalent antimonial, amphotericin B and pentamidine. These drugs, administered parenterally, cause several side effects and have a varied clinical response, depending on the species of Leishmania. Urgent expansion of the therapeutic arsenal against the disease is therefore necessary. Pammomycin is an aminoglycoside antibiotic that has already been approved for the treatment of visceral leishmaniasis in Southeast Asia. Here, we provide an in vitro evaluation of the activity of paromomycin in fifteen clinical isolates from patients with tegumentary leishmaniasis at a reference center for the treatment of the disease. Furthermore, the in vitro susceptibility to this drug in reference strains of Leishmania species that are endemic in Brazil has also been evaluated. Among the clinical isolates, nine were typed as Leishmania (Viannia) braziliensis, five as L. (Leishmania) amazonensis and one as L. (V.) guyanensis. Although never exposed to paromomycin, we found variable susceptibility among these isolates and reference strains in promastigotes and intracellular amastigotes, with the drug being more active in the amastigote form of the parasite. This study provides a preclinical dataset that is useful for the evaluation of pammomycin in the treatment of tegumentary leishmaniasis caused by species that are endemic in Brazil. (AU)

FAPESP's process: 16/21171-6 - Paromomycin for the treatment of Tegumentary Leishmaniasis: investigation in vitro, in vivo and in the identification of molecular markers associated with susceptibility and resistance
Grantee:Adriano Cappellazzo Coelho
Support Opportunities: Research Grants - Young Investigators Grants
FAPESP's process: 18/03299-0 - Evaluation of the efficacy of paromomycin in the treatment of experimental cutaneous leishmaniasis
Grantee:Elizabeth Magiolo Coser
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 20/01948-1 - Evaluation of susceptibility in vitro of clinical and dog isolates of Leishmania spp. to alternative drugs
Grantee:Bianca Alves Ferreira
Support Opportunities: Scholarships in Brazil - Master